)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Kane Biotech
Kane Biotech (KNE) investor relations material
Kane Biotech Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary28 May, 2026
Executive summary
Revenue for Q1 2026 was $43,218, down from $412,513 in Q1 2025, reflecting a shift to human wound care and early commercialization of revyve products.
Net loss improved to $714,827 from $1,218,497 year-over-year, driven by lower operating expenses and a disciplined cost structure.
Strategic focus is on accelerating commercialization of the revyve wound care portfolio in North America.
Financial highlights
Gross loss for Q1 2026 was $3,899, compared to a gross profit of $42,447 in Q1 2025, due to early commercialization and market build-out.
Operating expenses decreased to $669,402 from $1,203,505 year-over-year, reflecting cost reductions in staffing, incentives, and product development.
Cash at March 31, 2026 was $395,058, with additional capital raised after quarter-end.
Outlook and guidance
Focus remains on converting commercial momentum into accelerating revenues and delivering long-term shareholder value.
Management believes the company is at an inflection point in its commercialization journey.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kane Biotech
- revyveⓇ disrupts biofilms and transforms chronic wound care, targeting a $423M+ US market.KNE
Investor presentation28 May 2026 - 2025 saw lower revenue but improved cost structure, with new funding and regulatory wins supporting 2026 growth.KNEQ4 202523 Apr 2026
- Clinically proven biofilm disruption technology targets a $423M+ US wound care market in 2026.KNEInvestor presentation23 Mar 2026
- $10.4M STEM sale gain drove $9.2M net income, debt elimination, and future growth momentum.KNEQ2 202422 Jan 2026
- Record Q3 revenue and first Revive/revyve sales drive growth, with major deals and funding secured.KNEQ3 202412 Jan 2026
- 2025 targets include clinical trial launches, expanded distribution, and cash flow positivity.KNEInvestor Update9 Jan 2026
- Revenue dropped sharply in Q3 2025, but clinical and regulatory progress for revyve advanced.KNEQ3 202511 Dec 2025
- Revenue plunged post-animal health sale; net loss narrowed, with new board and US focus.KNEQ2 20259 Sep 2025
- Revenue surged and losses narrowed as restructuring and cost-saving measures took effect.KNEQ1 202516 Jun 2025
Next Kane Biotech earnings date
Q2 202627 Aug, 2026
Kane Biotech
Next Kane Biotech earnings date
Q2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage